Head-to-head · free

Rapport Therapeutics vs Roche Holding AG

RAPP vs RHHBY — return on capital, cash generation, margins and balance sheet side by side.

RAPP

0 / 0

measures where RAPP leads

RHHBY

0 / 0

measures where RHHBY leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureRAPP · FY2025RHHBY
Revenue——
Net income(111.5M)—
Revenue growth (yearly, multi-year)——
Free cash flow(88.1M)—
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity-28.2%—
Gross margin——
Operating margin——
Net debt / EBITDA0.42x—

Figures are as reported by each company; latest fiscal year shown.

Where Rapport Therapeutics's cash went (FY2025)

Capital spending
$616000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full RAPP profile →

Where Roche Holding AG's cash went

Not reported yet.

Full RHHBY profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons